表紙
市場調査レポート

Evotec AG - 製品パイプライン分析

Evotec AG - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 277765
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
Evotec AG - 製品パイプライン分析 Evotec AG - Product Pipeline Review - 2016
出版日: 2016年04月13日 ページ情報: 英文 60 Pages
概要

Evotec AG は創薬提携・共同開発企業で、癌や神経および腎臓、心血管、炎症、疼痛、代謝性疾患、呼吸器疾患などの様々な治療分野において低分子薬剤の特定および開発をする他、様々なサービス事業を展開しています。

当レポートでは、Evotec AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Evotec AG の基本情報

Evotec AG の概要

  • 主要情報
  • 企業情報

Evotec AG :R&Dの概要

  • 主な治療範囲

Evotec AG :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Evotec AG :パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Evotec AG :薬剤プロファイル

  • EVT-201
  • EVT-401
  • Drug To Target KDM For Oncology
  • Drugs for Endometriosis
  • EVT-501
  • Insulin Sensitizer
  • Small Molecule to Antagonize B1 for Pain
  • Small Molecule to Antagonize P2X3 and P2X2/3
  • Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis
  • Small Molecules for Inflammation
  • Small Molecules for Neurodegeneration
  • Undisclosed Molecule for Pain
  • Drug For Anemia
  • Drug for Kidney Diseases
  • Drug for Solid Tumor and Leukemia
  • Drugs for Glioblastoma Multiforme
  • Drugs for TargetEEM
  • Drugs to Inhibit FGFR3 for Cancer
  • Drugs to Inhibit Isocitrate Dehydrogenase for Cancer
  • Induced Pluripotent Stem Cells For Amyotrophic Lateral Sclerosis
  • Small Molecule For Alzheimers Disease
  • Small Molecule to Inhibit BACE-1 for Alzheimers Disease
  • Small Molecule to Inhibit PGB for Bacterial Infections
  • Small Molecule To Inhibit Serine Racemase For Neurology
  • Small Molecules for Chronic Kidney Disease
  • Small Molecules for Huntington Disease
  • Small Molecules for Multiple Sclerosis
  • Small Molecules to Inhibit Kv1.3 for Autoimmune Disorders

Evotec AG :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Evotec AG :最近のパイプライン動向

Evotec AG :休止中のプロジェクト

Evotec AG :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • EVT-301
    • RG-1577
    • REN-1654
    • REN-213
    • REN-850

Evotec AG :企業発表

Evotec AG :本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08021CDB

Summary

Global Markets Direct's, 'Evotec AG - Product Pipeline Review - 2016', provides an overview of the Evotec AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG
  • The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Evotec AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Evotec AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Evotec AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Evotec AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Evotec AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Evotec AG Snapshot
    • Evotec AG Overview
    • Key Information
    • Key Facts
  • Evotec AG - Research and Development Overview
    • Key Therapeutic Areas
  • Evotec AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Evotec AG - Pipeline Products Glance
    • Evotec AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Evotec AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Evotec AG - Drug Profiles
    • EVT-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit KDM for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Endometriosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-070
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-601
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVT-801
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Type 1 Diabetes and Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Kidney Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit FGFR3 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chronic Kidney Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Dysferlinopathies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Huntington Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Neurodegenerative diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PGB for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Evotec AG - Pipeline Analysis
    • Evotec AG - Pipeline Products by Target
    • Evotec AG - Pipeline Products by Route of Administration
    • Evotec AG - Pipeline Products by Molecule Type
    • Evotec AG - Pipeline Products by Mechanism of Action
  • Evotec AG - Recent Pipeline Updates
  • Evotec AG - Dormant Projects
  • Evotec AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • EVT-301
      • sembragiline
      • ocaperidone
      • REN-1654
      • REN-213
      • REN-850
  • Evotec AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Evotec AG, Key Information
  • Evotec AG, Key Facts
  • Evotec AG - Pipeline by Indication, 2016
  • Evotec AG - Pipeline by Stage of Development, 2016
  • Evotec AG - Monotherapy Products in Pipeline, 2016
  • Evotec AG - Partnered Products in Pipeline, 2016
  • Evotec AG - Partnered Products/ Combination Treatment Modalities, 2016
  • Evotec AG - Out-Licensed Products in Pipeline, 2016
  • Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Evotec AG - Phase II, 2016
  • Evotec AG - Phase I, 2016
  • Evotec AG - Preclinical, 2016
  • Evotec AG - Discovery, 2016
  • Evotec AG - Pipeline by Target, 2016
  • Evotec AG - Pipeline by Route of Administration, 2016
  • Evotec AG - Pipeline by Molecule Type, 2016
  • Evotec AG - Pipeline Products by Mechanism of Action, 2016
  • Evotec AG - Recent Pipeline Updates, 2016
  • Evotec AG - Dormant Developmental Projects,2016
  • Evotec AG - Discontinued Pipeline Products, 2016
  • Evotec AG, Subsidiaries

List of Figures

  • Evotec AG - Pipeline by Top 10 Indication, 2016
  • Evotec AG - Pipeline by Stage of Development, 2016
  • Evotec AG - Monotherapy Products in Pipeline, 2016
  • Evotec AG - Partnered Products in Pipeline, 2016
  • Evotec AG - Out-Licensed Products in Pipeline, 2016
  • Evotec AG - Pipeline by Target, 2016
  • Evotec AG - Pipeline by Molecule Type, 2016
  • Evotec AG - Pipeline Products by Mechanism of Action, 2016
Back to Top